BeStock  
Stocks › COLL

Collegium Pharmaceutical COLL

US equityMarket cap rank #3524
$21.97 +$0.04 (+0.18%)
Market open · Oct 8, 10:00 am ET · After hours $21.93 0.00%
Open$22.03
Prev close$21.93
Day range$21.80 – $22.03
Volume32.5K
Market cap$681.05M
P/E (TTM)17.3
Dividend yield–

Earnings

Average move on report day±7.5%last 16 reports
Closed higher12 of 1675% of the time
Best reaction+13.4%
Worst reaction-18.6%

Stock move on the day after each report

+6.6%2023/Q3+10.8%2023/Q4-16.8%2024/Q1+0.5%2024/Q2-7.3%2024/Q3+2.2%2024/Q4+5.9%2025/Q1+10.7%2025/Q2+13.4%2025/Q3-3.3%2025/Q4+7.7%2026/Q1-18.6%2026/Q2
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q26 Aug 2026Pre Market±10.4%-18.55%Bigger than priced
2026/Q17 May 2026Pre Market±18.3%+7.72%Within range
2025/Q426 Feb 2026Pre Market±8.8%-3.34%Within range
2025/Q36 Nov 2025Pre Market±13.2%+13.42%Bigger than priced
2025/Q27 Aug 2025Pre Market±13.4%+10.72%Within range
2025/Q18 May 2025After Market±10.6%+5.94%Within range
2024/Q427 Feb 2025After Market±16.8%+2.22%Within range
2024/Q37 Nov 2024After Market±9.7%-7.35%Within range
2024/Q28 Aug 2024After Market±8.7%+0.51%Within range
2024/Q19 May 2024After Market±16.3%-16.80%Bigger than priced
2023/Q422 Feb 2024After Market±13.6%+10.79%Within range
2023/Q37 Nov 2023After Market±16.9%+6.60%Within range
2023/Q23 Aug 2023After Market±16.3%+6.68%Within range
2023/Q14 May 2023After Market±11.0%+3.20%Within range
2022/Q423 Feb 2023After Market±9.2%+0.94%Within range
2022/Q33 Nov 2022After Market–+4.49%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q2

By business line

  • BELBUCA$57.67M 28.9%
  • Jornay PM$46.06M 23.0%
  • Xtampza Extended-release (ER)$45.01M 22.5%
  • Nucynta Extended-release (ER)$15.72M 7.9%
  • Nucynta Immediate-release (IR)$14.36M 7.2%
  • Azstarys$12.91M 6.5%
  • Symproic$3.02M 1.5%
  • Nucynta Extended-release (ER) Authorized Generic (AG)$2.78M 1.4%
  • Nucynta Immediate-release (IR) Authorized Generic (AG)$2.36M 1.2%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$199.88M+6.3% YoY
Operating profit$3.70M-89.4% YoY
Net profit-$15.05M-225.6% YoY
Diluted EPS-$0.46-235.3% YoY
Free cash flow$70.83M-2.1% YoY
Operating cash flow$71.32M

Revenue, last 8 quarters

$159.3MSep '24$181.9MDec '24$177.8MMar '25$188.0MJun '25$209.4MSep '25$205.4MDec '25$193.5MMar '26$199.9MJun '26

Net profit, last 8 quarters

$9.3MSep '24$12.5MDec '24$2.4MMar '25$12.0MJun '25$31.5MSep '25$17.0MDec '25$14.5MMar '26$-15.1MJun '26

Profitability & balance sheet

Gross margin60.0%
Operating margin19.5%
Net margin5.9%
Return on equity17.6%
Return on assets2.6%
Return on invested capital7.1%
Current ratio1.03
Liabilities / assets85.4%
Cash & investments$129.47M
Total debt$1.09B
Net cash (debt)-$965.50M
Free cash flow / sales40.6%

Discussion

No comments yet — be the first to weigh in on COLL.

Leave a comment

Scroll to Top